Book contents
- Silva’s Diagnostic Renal Pathology
- Silva’s Diagnostic Renal Pathology
- Copyright page
- Dedication
- Contents
- Contributors
- Foreword
- Preface to the First Edition
- Preface to the Second Edition
- Abbreviations
- Chapter 1 Renal Development and Anatomy
- Chapter 2 Renal Biopsy: The Nephrologist’s Viewpoint
- Chapter 3 Algorithmic Approach to the Interpretation of Renal Biopsy
- Chapter 4 Glomerular Diseases Associated with Nephrotic Syndrome and Proteinuria
- Chapter 5 Glomerular Diseases Associated Primarily with Asymptomatic or Gross Hematuria
- Chapter 6 Infection-related Glomerulonephritis, Membranoproliferative Pattern of Glomerulonephritis, and Nephritic Syndrome
- Chapter 7 Glomerular Diseases Associated with Crescentic Glomerulonephritis (Rapidly Progressive Glomerulonephritis)
- Chapter 8 Systemic Lupus Erythematosus and Other Autoimmune Diseases (Mixed Connective Tissue Disease, Rheumatoid Arthritis, and Sjogren’s Syndrome)
- Chapter 9 Metabolic Diseases of the Kidney
- Chapter 10 Thrombotic Microangiopathies
- Chapter 11 Renal Diseases Associated with Hematopoietic Disorders or Organized Deposits
- Chapter 12 Tubulointerstitial Diseases
- Chapter 13 Hypertension and Vascular Diseases of the Kidney
- Chapter 14 Cystic and Developmental Diseases of the Kidney
- Chapter 15 The Aging Kidney and End-stage Renal Disease
- Chapter 16 Pathology of Renal Transplantation
- Chapter 17 Digital Renal Pathology
- Index
- References
Chapter 10 - Thrombotic Microangiopathies
Published online by Cambridge University Press: 01 March 2017
Book contents
- Silva’s Diagnostic Renal Pathology
- Silva’s Diagnostic Renal Pathology
- Copyright page
- Dedication
- Contents
- Contributors
- Foreword
- Preface to the First Edition
- Preface to the Second Edition
- Abbreviations
- Chapter 1 Renal Development and Anatomy
- Chapter 2 Renal Biopsy: The Nephrologist’s Viewpoint
- Chapter 3 Algorithmic Approach to the Interpretation of Renal Biopsy
- Chapter 4 Glomerular Diseases Associated with Nephrotic Syndrome and Proteinuria
- Chapter 5 Glomerular Diseases Associated Primarily with Asymptomatic or Gross Hematuria
- Chapter 6 Infection-related Glomerulonephritis, Membranoproliferative Pattern of Glomerulonephritis, and Nephritic Syndrome
- Chapter 7 Glomerular Diseases Associated with Crescentic Glomerulonephritis (Rapidly Progressive Glomerulonephritis)
- Chapter 8 Systemic Lupus Erythematosus and Other Autoimmune Diseases (Mixed Connective Tissue Disease, Rheumatoid Arthritis, and Sjogren’s Syndrome)
- Chapter 9 Metabolic Diseases of the Kidney
- Chapter 10 Thrombotic Microangiopathies
- Chapter 11 Renal Diseases Associated with Hematopoietic Disorders or Organized Deposits
- Chapter 12 Tubulointerstitial Diseases
- Chapter 13 Hypertension and Vascular Diseases of the Kidney
- Chapter 14 Cystic and Developmental Diseases of the Kidney
- Chapter 15 The Aging Kidney and End-stage Renal Disease
- Chapter 16 Pathology of Renal Transplantation
- Chapter 17 Digital Renal Pathology
- Index
- References
- Type
- Chapter
- Information
- Silva's Diagnostic Renal Pathology , pp. 347 - 384Publisher: Cambridge University PressPrint publication year: 2017
References
George, JN, Nester, CM. Syndromes of thrombotic microangiopathy. The New England Journal of Medicine. 2014;371(19):1847.Google Scholar
Moschcowitz, E. An acute febrile pleiochromic anemia with hyaline thrombosis of the terminal arterioles and capillaries: an undescribed disease. Archives of Internal Medicine. 1925;36(1):89–93.Google Scholar
Baehr, G, Klemperer, P, Schifrin, A. An acute febrile anemia and thrombocytopenic purpura with diffuse platelet thromboses of capillaries and arterioles. Transactions of the Association of Amercian Physicians. 1936;51:43–58.Google Scholar
Singer, K, Bornstein, FP, Wile, SA. Thrombotic thrombocytopenic purpura: hemorrhagic diathesis with generalized platelet thromboses. Blood. 1947;2:542–54.Google Scholar
George, JN. Clinical practice. Thrombotic thrombocytopenic purpura. The New England Journal of Medicine. 2006;354(18):1927.CrossRefGoogle ScholarPubMed
George, JN, Chen, Q, Deford, CC, Al-Nouri, Z. Ten patient stories illustrating the extraordinarily diverse clinical features of patients with thrombotic thrombocytopenic purpura and severe ADAMTS13 deficiency. Journal of Clinical Apheresis. 2012;27(6):302.Google Scholar
Vesely, SK, George, JN, Lammle, B, et al. ADAMTS13 activity in thrombotic thrombocytopenic purpura–hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood. 2003;102(1):60.Google Scholar
Meloni, F, Solari, N, Cavagna, L, et al. Frequency of Th1, Th2 and Th17 producing T lymphocytes in bronchoalveolar lavage of patients with systemic sclerosis. Clinical and Experimental Rheumatology. 2009;27(5):765.Google Scholar
Coppo, P, Wolf, M, Veyradier, A, et al. Prognostic value of inhibitory anti-ADAMTS13 antibodies in adult-acquired thrombotic thrombocytopenic purpura. British Journal of Haematology. 2006;132(1):66.Google Scholar
Zafrani, L, Mariotte, E, Darmon, M, et al. Acute renal failure is prevalent in patients with thrombotic thrombocytopenic purpura associated with low plasma ADAMTS13 activity. Journal of Thrombosis and Haemostasis. 2015;13(3):380.Google Scholar
George, JN. How I treat patients with thrombotic thrombocytopenic purpura–hemolytic uremic syndrome. Blood. 2000;96(4):1223.CrossRefGoogle Scholar
George, JN. How I treat patients with thrombotic thrombocytopenic purpura: 2010. Blood. 2010; 116(20):4060.Google Scholar
Hovinga, JA, Vesely, SK, Terrell, DR, Lammle, B, George, JN. Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood. 2010;115(8):1500.Google Scholar
Froehlich-Zahnd, R, George, JN, Vesely, SK, et al. Evidence for a role of anti-ADAMTS13 autoantibodies despite normal ADAMTS13 activity in recurrent thrombotic thrombocytopenic purpura. Haematologica. 2012;97(2):297.CrossRefGoogle ScholarPubMed
Moatti-Cohen, M, Garrec, C, Wolf, M, et al. Unexpected frequency of Upshaw–Schulman syndrome in pregnancy-onset thrombotic thrombocytopenic purpura. Blood. 2012;119(24):5888.Google Scholar
Fujimura, Y, Matsumoto, M, Isonishi, A, et al. Natural history of Upshaw–Schulman syndrome based on ADAMTS13 gene analysis in Japan. Journal of Thrombosis and Haemostasis. 2011;9(Suppl 1):283.Google Scholar
Uchida, T, Wada, H, Mizutani, M, et al. Identification of novel mutations in ADAMTS13 in an adult patient with congenital thrombotic thrombocytopenic purpura. Blood. 2004;104(7):2081.Google Scholar
Furlan, M, Lammle, B. Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome: the role of von Willebrand factor-cleaving protease. Best Practice & Research in Clinical Haematology. 2001;14(2):437.Google Scholar
Reese, JA, Muthurajah, DS, Kremer Hovinga, JA, et al. Children and adults with thrombotic thrombocytopenic purpura associated with severe, acquired ADAMTS13 deficiency: comparison of incidence, demographic and clinical features. Pediatric Blood & Cancer. 2013;60(10):1676.CrossRefGoogle ScholarPubMed
Gasser, C, Gautier, E, Steck, A, Siebenmann, RE, Oechslin, R. [Hemolytic-uremic syndrome: bilateral necrosis of the renal cortex in acute acquired hemolytic anemia]. Schweiz Med Wochenschr. 1955;85(38–39):905.Google Scholar
Kaplan, BS, Chesney, RW, Drummond, KN. Hemolytic uremic syndrome in families. The New England Journal of Medicine. 1975;292(21):1090.Google Scholar
Sullivan, M, Rybicki, LA, Winter, A, et al. Age-related penetrance of hereditary atypical hemolytic uremic syndrome. Annals of Human Genetics. 2011;75(6):639.Google Scholar
Noris, M, Caprioli, J, Bresin, E, et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clinical Journal of the American Society of Nephrology. 2010;5(10):1844.Google Scholar
Loirat, C, Fremeaux-Bacchi, V. Atypical hemolytic uremic syndrome. Orphanet Journal of Rare Diseases. 2011;6:60.Google Scholar
Sellier-Leclerc, AL, Fremeaux-Bacchi, V, Dragon-Durey, MA, et al. Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome. Journal of the American Society of Nephrology. 2007;18(8):2392.Google Scholar
Legendre, CM, Licht, C, Muus, P, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. The New England journal of Medicine. 2013;368(23):2169.Google Scholar
Jokiranta, TS, Zipfel, PF, Fremeaux-Bacchi, V, et al. Where next with atypical hemolytic uremic syndrome? Molecular Immunology. 2007;44(16):3889.CrossRefGoogle ScholarPubMed
McMinn, JR, George, JN. Evaluation of women with clinically suspected thrombotic thrombocytopenic purpura–hemolytic uremic syndrome during pregnancy. Journal of Clinical Apheresis. 2001;16(4):202.Google Scholar
Constantinescu, AR, Bitzan, M, Weiss, LS, et al. Non-enteropathic hemolytic uremic syndrome: causes and short-term course. American Journal of Kidney Diseases. 2004;43(6):976.Google Scholar
Karmali, MA, Petric, M, Lim, C, et al. The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli. The Journal of Infectious Diseases. 1985;151(5):775.CrossRefGoogle Scholar
Karmali, MA, Petric, M, Lim, C, Fleming, PC, Steele, BT. Escherichia coli cytotoxin, haemolytic-uraemic syndrome, and haemorrhagic colitis. Lancet. 1983;2(8362):1299.Google Scholar
Neill, MA, Tarr, PI, Clausen, CR, Christie, DL, Hickman, RO. Escherichia coli O157: H7as the predominant pathogen associated with the hemolytic uremic syndrome: a prospective study in the Pacific Northwest. Pediatrics. 1987;80(1):37.CrossRefGoogle ScholarPubMed
Neill, MA, Agosti, J, Rosen, H. Hemorrhagic colitis with Escherichia coli O157: H7preceding adult hemolytic uremic syndrome. Archives of Internal Medicine. 1985;145(12):2215.CrossRefGoogle ScholarPubMed
Gorlova, O, Martin, JE, Rueda, B, et al. Identification of novel genetic markers associated with clinical phenotypes of systemic sclerosis through a genome-wide association strategy. PLoS Genetics. 2011;7(7):e1002178.Google Scholar
Wittenberg, DF. Emerging and re-emerging diseases – epidemic enterohaemorrhagic infections 100 years after Shiga. South African Medical Journal. 1999;89(7):750.Google Scholar
Lynn, RM, O’Brien, SJ, Taylor, CM, et al. Childhood hemolytic uremic syndrome, United Kingdom and Ireland. Emerging Infectious Diseases. 2005;11(4):590.Google Scholar
Bhimma, R, Rollins, NC, Coovadia, HM, Adhikari, M. Post-dysenteric hemolytic uremic syndrome in children during an epidemic of Shigella dysentery in Kwazulu/Natal. Pediatric Nephrology. 1997;11(5):560.Google Scholar
Rangel, JM, Sparling, PH, Crowe, C, Griffin, PM, Swerdlow, DL. Epidemiology of Escherichia coli O157: H7outbreaks, United States, 1982–2002. Emerging Infectious Diseases. 2005;11(4):603.CrossRefGoogle ScholarPubMed
Gerber, A, Karch, H, Allerberger, F, Verweyen, HM, Zimmerhackl, LB. Clinical course and the role of shiga toxin-producing Escherichia coli infection in the hemolytic-uremic syndrome in pediatric patients, 1997–2000, in Germany and Austria: a prospective study. The Journal of Infectious Diseases. 2002;186(4):493.Google Scholar
Frank, C, Werber, D, Cramer, JP, et al. Epidemic profile of Shiga-toxin-producing Escherichia coli O104: H4outbreak in Germany. The New England Journal of Medicine. 2011;365(19):1771.Google Scholar
Piercefield, EW, Bradley, KK, Coffman, RL, Mallonee, SM. Hemolytic uremic syndrome after an Escherichia coli O111 outbreak. Archives of Internal Medicine. 2010;170(18):1656.Google Scholar
Maki, DG. Don’t eat the spinach – controlling foodborne infectious disease. The New England Journal of Medicine. 2006;355(19):1952.Google Scholar
Tzschoppe, M, Martin, A, Beutin, L. A rapid procedure for the detection and isolation of enterohaemorrhagic Escherichia coli (EHEC) serogroup O26, O103, O111, O118, O121, O145 and O157 strains and the aggregative EHEC O104: H4 strain from ready-to-eat vegetables. International Journal of Food Microbiology. 2012;152(1–2):19.Google Scholar
Park, YA, Hay, SN, King, KE, et al. Is it quinine TTP/HUS or quinine TMA? ADAMTS13 levels and implications for therapy. Journal of Clinical Apheresis. 2009;24(3):115.Google Scholar
Knower, MT, Bowton, DL, Owen, J, Dunagan, DP. Quinine-induced disseminated intravascular coagulation: case report and review of the literature. Intensive Care Medicine. 2003;29(6):1007.Google Scholar
Blake-Haskins, JA, Lechleider, RJ, Kreitman, RJ. Thrombotic microangiopathy with targeted cancer agents. Clinical Cancer Research. 2011;17(18):5858.Google Scholar
Ntukidem, N, Arce-Lara, C, Otterson, GA, et al. Capped-dose mitomycin C: a pooled safety analysis from three prospective clinical trials. Cancer Chemotherapy and Pharmacology. 2010;65(2):319.Google Scholar
Reese, JA, Bougie, DW, Curtis, BR, et al. Drug-induced thrombotic microangiopathy: experience of the Oklahoma Registry and the BloodCenter of Wisconsin. American Journal of Hematology. 2015;90(5):406.Google Scholar
Eremina, V, Jefferson, JA, Kowalewska, J, et al. VEGF inhibition and renal thrombotic microangiopathy. The New England Journal of Medicine. 2008;358(11):1129.Google Scholar
Broen, JC, Coenen, MJ, Radstake, TR. Genetics of systemic sclerosis: an update. Current Rheumatology Reports. 2012;14(1):11.Google Scholar
Medina, PJ, Sipols, JM, George, JN. Drug-associated thrombotic thrombocytopenic purpura–hemolytic uremic syndrome. Current Opinion in Hematology. 2001;8(5):286.CrossRefGoogle ScholarPubMed
Karkowski, L, Wolf, M, Lescampf, J, et al. [Clopidogrel induced thrombotic thrombocytopenic purpura]. La Revue de medecine interne. 2011;32(12):762.Google Scholar
Zakarija, A, Kwaan, HC, Moake, JL, et al. Ticlopidine- and clopidogrel-associated thrombotic thrombocytopenic purpura (TTP): review of clinical, laboratory, epidemiological, and pharmacovigilance findings (1989–2008). Kidney International. 2009;112(Suppl):S20.Google Scholar
Bennett, CL, Kim, B, Zakarija, A, et al. Two mechanistic pathways for thienopyridine-associated thrombotic thrombocytopenic purpura: a report from the SERF-TTP Research Group and the RADAR Project. Journal of the American College of Cardiology. 2007;50(12):1138.CrossRefGoogle Scholar
Menni, F, Testa, S, Guez, S, et al. Neonatal atypical hemolytic uremic syndrome due to methylmalonic aciduria and homocystinuria. Pediatric Nephrology. 2012;27(8):1401.Google Scholar
Russo, P, Doyon, J, Sonsino, E, Ogier, H, Saudubray, JM. A congenital anomaly of vitamin B12 metabolism: a study of three cases. Human Pathology. 1992;23(5):504.Google Scholar
Geraghty, MT, Perlman, EJ, Martin, LS, et al. Cobalamin C defect associated with hemolytic-uremic syndrome. The Journal of Pediatrics. 1992;120(6):934.Google Scholar
Fischer, S, Huemer, M, Baumgartner, M, et al. Clinical presentation and outcome in a series of 88 patients with the cblC defect. Journal of Inherited Metabolic Disease. 2014;37(5):831.Google Scholar
Cornec-Le Gall, E, Delmas, Y, De Parscau, L, et al. Adult-onset eculizumab-resistant hemolytic uremic syndrome associated with cobalamin C deficiency. American Journal of Hidney Diseases. 2014;63(1):119.Google Scholar
Sharma, AP, Greenberg, CR, Prasad, AN, Prasad, C. Hemolytic uremic syndrome (HUS) secondary to cobalamin C (cblC) disorder. Pediatric Nephrology. 2007;22(12):2097.Google Scholar
Delvaeye, M, Noris, M, De Vriese, A, et al. Thrombomodulin mutations in atypical hemolytic-uremic syndrome. The New England Journal of Medicine. 2009;361(4):345.Google Scholar
Bu, F, Maga, T, Meyer, NC, et al. Comprehensive genetic analysis of complement and coagulation genes in atypical hemolytic uremic syndrome. Journal of the American Society of Nephrology. 2014;25(1):55.CrossRefGoogle ScholarPubMed
Ozaltin, F, Li, B, Rauhauser, A, et al. DGKE variants cause a glomerular microangiopathy that mimics membranoproliferative GN. Journal of the American Society of Nephrology. 2013;24(3):377.Google Scholar
Lemaire, M, Fremeaux-Bacchi, V, Schaefer, F, et al. Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome. Nature Genetics. 2013;45(5):531.Google Scholar
Mele, C, Lemaire, M, Iatropoulos, P, et al. Characterization of a new DGKE intronic mutation in genetically unsolved cases of familial atypical hemolytic uremic syndrome. Clinical Journal of the American Society of Nephrology. 2015;10(6):1011.Google Scholar
Booth, KK, Terrell, DR, Vesely, SK, George, JN. Systemic infections mimicking thrombotic thrombocytopenic purpura. American Journal of Hematology. 2011;86(9):743.Google Scholar
Chu, QD, Medeiros, LJ, Fisher, AE, Chaquette, RF, Crowley, JP. Thrombotic thrombocytopenic purpura and HIV infection. Southern Medical Journal. 1995;88(1):82.Google Scholar
Thompson, CE, Damon, LE, Ries, CA, Linker, CA. Thrombotic microangiopathies in the 1980s: clinical features, response to treatment, and the impact of the human immunodeficiency virus epidemic. Blood. 1992;80(8):1890.Google Scholar
Ucar, A, Fernandez, HF, Byrnes, JJ, Lian, EC, Harrington, WJ Jr. Thrombotic microangiopathy and retroviral infections: a 13-year experience. American Journal of Hematology. 1994;45(4):304.Google Scholar
Sutor, GC, Schmidt, RE, Albrecht, H. Thrombotic microangiopathies and HIV infection: report of two typical cases, features of HUS and TTP, and review of the literature. Infection. 1999;27(1):12.Google Scholar
Becker, S, Fusco, G, Fusco, J, et al. HIV-associated thrombotic microangiopathy in the era of highly active antiretroviral therapy: an observational study. Clinical Infectious Diseases. 2004;39(Suppl 5):S267.Google Scholar
Gervasoni, C, Ridolfo, AL, Vaccarezza, M, et al. Thrombotic microangiopathy in patients with acquired immunodeficiency syndrome before and during the era of introduction of highly active antiretroviral therapy. Clinical Infectious Diseases. 2002;35(12):1534.Google Scholar
Bell, WR, Chulay, JD, Feinberg, JE. Manifestations resembling thrombotic microangiopathy in patients with advanced human immunodeficiency virus (HIV) disease in a cytomegalovirus prophylaxis trial (ACTG 204). Medicine. 1997;76(5):369.Google Scholar
Pene, F, Vigneau, C, Auburtin, M, et al. Outcome of severe adult thrombotic microangiopathies in the intensive care unit. Intensive Care Medicine. 2005;31(1):71.Google Scholar
Outschoorn, UM, Ferber, A. Outcomes in the treatment of thrombotic thrombocytopenic purpura with splenectomy: a retrospective cohort study. American Journal of Hematology. 2006;81(12):895.CrossRefGoogle ScholarPubMed
Gunther, K, Garizio, D, Nesara, P. ADAMTS13 activity and the presence of acquired inhibitors in human immunodeficiency virus-related thrombotic thrombocytopenic purpura. Transfusion. 2007;47(9):1710.Google Scholar
Benjamin, M, Terrell, DR, Vesely, SK, et al. Frequency and significance of HIV infection among patients diagnosed with thrombotic thrombocytopenic purpura. Clinical Infectious Diseases. 2009;48(8):1129.Google Scholar
Malak, S, Wolf, M, Millot, GA, et al. Human immunodeficiency virus-associated thrombotic microangiopathies: clinical characteristics and outcome according to ADAMTS13 activity. Scandinavian Journal of Immunology. 2008;68(3):337.Google Scholar
Hart, D, Sayer, R, Miller, R, et al. Human immunodeficiency virus associated thrombotic thrombocytopenic purpura – favourable outcome with plasma exchange and prompt initiation of highly active antiretroviral therapy. British Journal of Haematology. 2011;153(4):515.Google Scholar
Moore, RD. Schistocytosis and a thrombotic microangiopathy-like syndrome in hospitalized HIV-infected patients. American Journal of Hematology. 1999;60(2):116.Google Scholar
Park, YA, Hay, SN, Brecher, ME. ADAMTS13 activity levels in patients with human immunodeficiency virus-associated thrombotic microangiopathy and profound CD4 deficiency. Journal of Clinical Apheresis. 2009;24(1):32.Google Scholar
Maslo, C, Peraldi, MN, Desenclos, JC, et al. Thrombotic microangiopathy and cytomegalovirus disease in patients infected with human immunodeficiency virus. Clinical Infectious Diseases. 1997;24(3):350.Google Scholar
Kosugi, N, Tsurutani, Y, Isonishi, A, et al. Influenza A infection triggers thrombotic thrombocytopenic purpura by producing the anti-ADAMTS13 IgG inhibitor. Internal Medicine. 2010;49(7):689.Google Scholar
Huang, YH, Lin, TY, Wong, KS, et al. Hemolytic uremic syndrome associated with pneumococcal pneumonia in Taiwan. European Journal of Pediatrics. 2006;165(5):332.CrossRefGoogle ScholarPubMed
Lee, CF, Liu, SC, Lue, KH, Chen, JP, Sheu, JN. Pneumococcal pneumonia with empyema and hemolytic uremic syndrome in children: report of three cases. Journal of Microbiology, Immunology, and Infection. 2006;39(4):348.Google Scholar
Waters, AM, Kerecuk, L, Luk, D, et al. Hemolytic uremic syndrome associated with invasive pneumococcal disease: the United Kingdom experience. The Journal of Pediatrics. 2007;151(2):140.Google Scholar
Chautemps, N, Milesi, C, Cambonie, G, et al. [Pneumococcal hemolytic uremic syndrome: about 2 cases]. Archives de Pediatrie. 2008;15(7):1206.Google Scholar
Hopkins, CK, Yuan, S, Lu, Q, Ziman, A, Goldfinger, D. A severe case of atypical hemolytic uremic syndrome associated with pneumococcal infection and T activation treated successfully with plasma exchange. Transfusion. 2008;48(11):2448.Google Scholar
Prestidge, C, Wong, W. Ten years of pneumococcal-associated haemolytic uraemic syndrome in New Zealand children. Journal of Paediatrics and Child Health. 2009;45(12):731.Google Scholar
Bender, JM, Ampofo, K, Byington, CL, et al. Epidemiology of Streptococcus pneumoniae-induced hemolytic uremic syndrome in Utah children. The Pediatric Infectious Disease Journal. 2010;29(8):712.Google Scholar
Copelovitch, L, Kaplan, BS. Streptococcus pneumoniae-associated hemolytic uremic syndrome: classification and the emergence of serotype 19A. Pediatrics. 2010;125(1):e174.Google Scholar
Banerjee, R, Hersh, AL, Newland, J, et al. Streptococcus pneumoniae-associated hemolytic uremic syndrome among children in North America. The Pediatric Infectious Disease Journal. 2011;30(9):736.Google Scholar
Chen, SY, Wu, CY, Tsai, IJ, Tsau, YK, Su, YT. Nonenteropathic hemolytic uremic syndrome: the experience of a medical center. Pediatrics and Neonatology. 2011;52(2):73.Google Scholar
Pelras, S, Delmas, Y, Lamireau, D, et al. Severe transient ADAMTS13 deficiency in pneumococcal-associated hemolytic uremic syndrome. Pediatric Nephrology. 2011;26(4):631.Google Scholar
Lee, CS, Chen, MJ, Chiou, YH, et al. Invasive pneumococcal pneumonia is the major cause of paediatric haemolytic-uraemic syndrome in Taiwan. Nephrology (Carlton). 2012;17(1):48.Google Scholar
Quiviger, S, Flechelles, O, Cecile, W, Hatchuel, Y. [Streptococcus pneumoniae-induced hemolytic uremic syndrome: A serotype-3-associated case]. Archives de Pediatrie. 2012;19(6):599.Google Scholar
Cabrera, GR, Fortenberry, JD, Warshaw, BL, et al. Hemolytic uremic syndrome associated with invasive Streptococcus pneumoniae infection. Pediatrics. 1998;101(4 Pt 1):699.Google Scholar
Nathanson, S, Deschenes, G. Prognosis of Streptococcus pneumoniae-induced hemolytic uremic syndrome. Pediatric Nephrology. 2001;16(4):362.Google Scholar
Brandt, J, Wong, C, Mihm, S, et al. Invasive pneumococcal disease and hemolytic uremic syndrome. Pediatrics. 2002;110(2 Pt 1):371.Google Scholar
Francis, KK, Kalyanam, N, Terrell, DR, Vesely, SK, George, JN. Disseminated malignancy misdiagnosed as thrombotic thrombocytopenic purpura: a report of 10 patients and a systematic review of published cases. The Oncologist. 2007;12(1):11.Google Scholar
Alonso, JV, Fonseca, J, Lopera, EL, et al. A report of disseminated adenocarcinoma presenting as thrombotic thrombocytopenic purpura. Hematology Reports. 2011;3(2):e14.Google Scholar
Lechner, K, Obermeier, HL. Cancer-related microangiopathic hemolytic anemia: clinical and laboratory features in 168 reported cases. Medicine. 2012;91(4):195.Google Scholar
Vasko, R, Koziolek, M, Fuzesi, L, et al. Fulminant plasmapheresis-refractory thrombotic microangiopathy associated with advanced gastric cancer. Therapeutic Apheresis and Dialysis. 2010;14(2):222.Google Scholar
Fontana, S, Gerritsen, HE, Kremer Hovinga, J, Furlan, M, Lammle, B. Microangiopathic haemolytic anaemia in metastasizing malignant tumours is not associated with a severe deficiency of the von Willebrand factor-cleaving protease. British Journal of Haematology. 2001;113(1):100.Google Scholar
Lohrmann, HP, Brech, W, Widmer, K, Heimpel, H. [Hemolytic-uremic syndrome in adults]. Dtsch Med Wochenschr. 1973;98(2):54.Google Scholar
Favre, GA, Touzot, M, Fremeaux-Bacchi, V, et al. Malignancy and thrombotic microangiopathy or atypical haemolytic and uraemic syndrome? British Journal of Haematology. 2014;166(5):802.Google Scholar
Fakhouri, F, Roumenina, L, Provot, F, et al. Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations. Journal of the American Society of Nephrology. 2010;21(5):859.Google Scholar
Reveille, JD. Ethnicity and race and systemic sclerosis: how it affects susceptibility, severity, antibody genetics, and clinical manifestations. Current Rheumatology Reports. 2003;5(2):160.Google Scholar
Calderazzo, JC, Kempfer, A, Powazniak, Y, et al. A new ADAMTS13 missense mutation (D1362V) in thrombotic thrombocytopenic purpura diagnosed during pregnancy. Thrombosis and Haemostasis. 2012; 108(2).Google ScholarPubMed
Ducloy-Bouthors, AS, Caron, C, Subtil, D, et al. Thrombotic thrombocytopenic purpura: medical and biological monitoring of six pregnancies. European Journal of Obstetrics, Gynecology, and Reproductive Biology. 2003;111(2):146.Google Scholar
Terrell, DR, Williams, LA, Vesely, SK, et al. The incidence of thrombotic thrombocytopenic purpura–hemolytic uremic syndrome: all patients, idiopathic patients, and patients with severe ADAMTS-13 deficiency. Journal of Thrombosis and Haemostasis. 2005;3(7):1432.Google Scholar
Martin, JN Jr., Bailey, AP, Rehberg, JF, et al. Thrombotic thrombocytopenic purpura in 166 pregnancies: 1955–2006. American Journal of Obstetrics and Gynecology. 2008;199(2):98.Google Scholar
Salmon, JE, Heuser, C, Triebwasser, M, et al. Mutations in complement regulatory proteins predispose to preeclampsia: a genetic analysis of the PROMISSE cohort. PLoS Medicine. 2011;8(3):e1001013.Google Scholar
Hulstein, JJ, van Runnard Heimel, PJ, Franx, A, et al. Acute activation of the endothelium results in increased levels of active von Willebrand factor in hemolysis, elevated liver enzymes and low platelets (HELLP) syndrome. Journal of Thrombosis and Haemostasis. 2006;4(12):2569.Google Scholar
Ranque, B, Mouthon, L. Geoepidemiology of systemic sclerosis. Autoimmunity Reviews. 2010;9(5):A311.Google Scholar
Mayes, MD, Lacey, JV Jr., Beebe-Dimmer, J, et al. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis and Rheumatism. 2003;48(8):2246.Google Scholar
Bohle, A, Helmchen, U, Grund, KE, et al. Malignant nephrosclerosis in patients with hemolytic uremic syndrome (primary malignant nephrosclerosis). Current Topics in Pathology. 1977;65:81.Google Scholar
Zhang, B, Xing, C, Yu, X, et al. Renal thrombotic microangiopathies induced by severe hypertension. Hypertension Research. 2008;31(3):479.Google Scholar
Shibagaki, Y, Fujita, T. Thrombotic microangiopathy in malignant hypertension and hemolytic uremic syndrome (HUS)/ thrombotic thrombocytopenic purpura (TTP): can we differentiate one from the other? Hypertension Research. 2005;28(1):89.Google Scholar
Shavit, L, Reinus, C, Slotki, I. Severe renal failure and microangiopathic hemolysis induced by malignant hypertension – case series and review of literature. Clinical Nephrology. 2010;73(2):147.Google Scholar
van den Born, BJ, Lowenberg, EC, van der Hoeven, NV, et al. Endothelial dysfunction, platelet activation, thrombogenesis and fibrinolysis in patients with hypertensive crisis. Journal of Hypertension. 2011;29(5):922.Google Scholar
Hernandez-Molina, G, Garcia-Trejo, LP, Uribe, N, Cabral, AR. Thrombotic microangiopathy and poor renal outcome in lupus patients with or without antiphospholipid syndrome. Clinical and Experimental Rheumatology. 2015;33(4):503.Google Scholar
Song, D, Wu, LH, Wang, FM, et al. The spectrum of renal thrombotic microangiopathy in lupus nephritis. Arthritis Research & Therapy. 2013;15(1):R12.Google Scholar
Starck, M, Abedinpour, F, Dendorfer, U, et al. Acquired thrombotic thrombocytopenic purpura as the presenting symptom of systemic lupus erythematosus. Successful treatment with plasma exchange and immunosuppression – report of two cases. European Journal of Haematology. 2005;75(5):436.Google Scholar
Gungor, T, Furlan, M, Lammle, B, Kuhn, F, Seger, RA. Acquired deficiency of von Willebrand factor-cleaving protease in a patient suffering from acute systemic lupus erythematosus. Rheumatology (Oxford). 2001;40(8):940.Google Scholar
Matsuyama, T, Kuwana, M, Matsumoto, M, et al. Heterogeneous pathogenic processes of thrombotic microangiopathies in patients with connective tissue diseases. Thrombosis and Haemostasis. 2009;102(2):371.Google Scholar
Hunt, BJ, Tueger, S, Pattison, J, Cavenagh, J, D’Cruz, DP. Microangiopathic haemolytic anaemia secondary to lupus nephritis: an important differential diagnosis of thrombotic thrombocytopenic purpura. Lupus. 2007;16(5):358.Google Scholar
George, JN, Vesely, SK, James, JA. Overlapping features of thrombotic thrombocytopenic purpura and systemic lupus erythematosus. Southern Medical Journal. 2007;100(5):512.Google Scholar
Chifflot, H, Fautrel, B, Sordet, C, Chatelus, E, Sibilia, J. Incidence and prevalence of systemic sclerosis: a systematic literature review. Seminars in Arthritis and Rheumatism. 2008;37(4):223.Google Scholar
Barnes, J, Mayes, MD. Epidemiology of systemic sclerosis: incidence, prevalence, survival, risk factors, malignancy, and environmental triggers. Current Opinion in Rheumatology. 2012;24(2):165.Google Scholar
LeRoy, EC, Black, C, Fleischmajer, R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. Journal of Rheumatology. 1988;15(2):202.Google Scholar
Batal, I, Domsic, RT, Medsger, TA, Bastacky, S. Scleroderma renal crisis: a pathology perspective. International Journal of Rheumatology. 2010;2010:543704.Google Scholar
Shanmugam, VK, Steen, VD. Renal disease in scleroderma: an update on evaluation, risk stratification, pathogenesis and management. Current Opinion in Rheumatology. 2012;24(6):669.Google Scholar
Walker, UA, Tyndall, A, Czirjak, L, et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database. Annals of the Rheumatic Diseases. 2007;66(6):754.Google Scholar
Saeed, F, Parke, A. Normotensive scleroderma renal crisis in a patient with progressive systemic sclerosis: case report and review of literature. Connecticut Medicine. 2011;75(2):83.Google Scholar
Penn, H, Howie, AJ, Kingdon, EJ, et al. Scleroderma renal crisis: patient characteristics and long-term outcomes. Quarterly Journal of Medicine. 2007;100(8):485.Google Scholar
Cozzi, F, Marson, P, Cardarelli, S, et al. Prognosis of scleroderma renal crisis: a long-term observational study. Nephrology, dialysis, transplantation. 2012;27(12):4398–403.Google Scholar
Nikpour, M, Hissaria, P, Byron, J, et al. Prevalence, correlates and clinical usefulness of antibodies to RNA polymerase III in systemic sclerosis: a cross-sectional analysis of data from an Australian cohort. Arthritis Research & Therapy. 2011;13(6):R211.Google Scholar
Nguyen, B, Assassi, S, Arnett, FC, Mayes, MD. Association of RNA polymerase III antibodies with scleroderma renal crisis. The Journal of Rheumatology. 2010;37(5):1068; author reply 1069.Google Scholar
Hesselstrand, R, Scheja, A, Wuttge, DM. Scleroderma renal crisis in a Swedish systemic sclerosis cohort: survival, renal outcome, and RNA polymerase III antibodies as a risk factor. Scandinavian Journal of Rheumatology. 2012;41(1):39.Google Scholar
Graf, SW, Hakendorf, P, Lester, S, et al. South Australian Scleroderma Register: autoantibodies as predictive biomarkers of phenotype and outcome. International Journal of Rheumatic Diseases. 2012;15(1):102.Google Scholar
Miyakis, S, Lockshin, MD, Atsumi, T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). Journal of Thrombosis and Haemostasis. 2006;4(2):295.Google Scholar
Cervera, R, Font, J, Gomez-Puerta, JA, et al. Validation of the preliminary criteria for the classification of catastrophic antiphospholipid syndrome. Annals of the Rheumatic Diseases. 2005;64(8):1205.Google Scholar
Cervera, R, Espinosa, G. Update on the catastrophic antiphospholipid syndrome and the “CAPS Registry”. Seminars in Thrombosis and Hemostasis. 2012;38(4):333.Google ScholarPubMed
Espinosa, G, Bucciarelli, S, Cervera, R, et al. Thrombotic microangiopathic haemolytic anaemia and antiphospholipid antibodies. Annals of the Rheumatic Diseases. 2004;63(6):730.Google Scholar
Nochy, D, Daugas, E, Droz, D, et al. The intrarenal vascular lesions associated with primary antiphospholipid syndrome. Journal of the American Society of Nephrology. 1999;10(3):507.Google Scholar
Daugas, E, Nochy, D, Huong, DL, et al. Antiphospholipid syndrome nephropathy in systemic lupus erythematosus. Journal of the American Society of Nephrology. 2002;13(1):42.Google Scholar
Asherson, RA, Cervera, R. Microvascular and microangiopathic antiphospholipid-associated syndromes (“MAPS”): semantic or antisemantic? Autoimmunity Reviews. 2008;7(3):164.Google Scholar
Fischer, MJ, Rauch, J, Levine, JS. The antiphospholipid syndrome. Seminars in Nephrology. 2007;27(1):35.Google Scholar
Tektonidou, MG, Sotsiou, F, Moutsopoulos, HM. Antiphospholipid syndrome (APS) nephropathy in catastrophic, primary, and systemic lupus erythematosus-related APS. The Journal of Rheumatology. 2008;35(10):1983.Google Scholar
Ho, VT, Cutler, C, Carter, S, et al. Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation. Biology of Blood and Marrow Transplantation. 2005;11(8):571.Google Scholar
George, JN, Li, X, McMinn, JR, et al. Thrombotic thrombocytopenic purpura–hemolytic uremic syndrome following allogeneic HPC transplantation: a diagnostic dilemma. Transfusion. 2004;44(2):294.Google Scholar
Labrador, J, Lopez-Corral, L, Lopez-Godino, O, et al. Risk factors for thrombotic microangiopathy in allogeneic hematopoietic stem cell recipients receiving GVHD prophylaxis with tacrolimus plus MTX or sirolimus. Bone Marrow Transplantation. 2014;49(5):684.Google Scholar
Ruutu, T, Barosi, G, Benjamin, RJ, et al. Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group. Haematologica. 2007;92(1):95.Google Scholar
Changsirikulchai, S, Myerson, D, Guthrie, KA, et al. Renal thrombotic microangiopathy after hematopoietic cell transplant: role of GVHD in pathogenesis. Clinical Journal of the American Society of Nephrology. 2009;4(2):345.Google Scholar
Raife, TJ, Lager, DJ. Chronic thrombotic microangiopathy associated with antineoplastic therapy with minimal hematologic effects. Mayo Clinic Proceedings. 2002;77(4):323.Google Scholar
Troxell, ML, Pilapil, M, Miklos, DB, Higgins, JP, Kambham, N. Renal pathology in hematopoietic cell transplantation recipients. Modern Pathology. 2008;21(4):396.Google Scholar
Siami, K, Kojouri, K, Swisher, KK, et al. Thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation: an autopsy study. Transplantation. 2008;85(1):22.Google Scholar
Reynolds, JC, Agodoa, LY, Yuan, CM, Abbott, KC. Thrombotic microangiopathy after renal transplantation in the United States. American Journal of Kidney Diseases. 2003;42(5):1058.Google Scholar
Zarifian, A, Meleg-Smith, S, O’Donovan, R, Tesi, RJ, Batuman, V. Cyclosporine-associated thrombotic microangiopathy in renal allografts. Kidney International. 1999;55(6):2457.Google Scholar
Pham, PT, Peng, A, Wilkinson, AH, et al. Cyclosporine and tacrolimus-associated thrombotic microangiopathy. American Journal of Kidney Diseases. 2000;36(4):844.Google Scholar
Satoskar, AA, Pelletier, R, Adams, P, et al. De novo thrombotic microangiopathy in renal allograft biopsies-role of antibody-mediated rejection. American Journal of Transplantation. 2010;10(8):1804.CrossRefGoogle ScholarPubMed
Meehan, SM, Kremer, J, Ali, FN, et al. Thrombotic microangiopathy and peritubular capillary C4d expression in renal allograft biopsies. Clinical Journal of the American Society of Nephrology. 2011;6(2):395.Google Scholar
Schwimmer, J, Nadasdy, TA, Spitalnik, PF, Kaplan, KL, Zand, MS. De novo thrombotic microangiopathy in renal transplant recipients: a comparison of hemolytic uremic syndrome with localized renal thrombotic microangiopathy. American Journal of Kidney Diseases. 2003;41(2):471.CrossRefGoogle ScholarPubMed
Said, T, Al-Otaibi, T, Al-Wahaib, S, et al. Posttransplantation calcineurin inhibitor-induced hemolytic uremic syndrome: single-center experience. Transplantation Proceedings. 2010;42(3):814.Google Scholar
Le Quintrec, M, Lionet, A, Kamar, N, et al. Complement mutation-associated de novo thrombotic microangiopathy following kidney transplantation. American Journal of Transplantation. 2008;8(8):1694.Google Scholar
Bresin, E, Daina, E, Noris, M, et al. Outcome of renal transplantation in patients with non-Shiga toxin-associated hemolytic uremic syndrome: prognostic significance of genetic background. Clinical Journal of the American Society of Nephrology. 2006;1(1):88.Google Scholar
Loirat, C, Fremeaux-Bacchi, V. Hemolytic uremic syndrome recurrence after renal transplantation. Pediatric Transplantation. 2008;12(6):619.Google Scholar
Noris, M, Remuzzi, G. Thrombotic microangiopathy after kidney transplantation. American Journal of Transplantation. 2010;10(7):1517.Google Scholar
Zuber, J, Le Quintrec, M, Sberro-Soussan, R, et al. New insights into postrenal transplant hemolytic uremic syndrome. Nature Reviews Nephrology. 2011;7(1):23.Google Scholar
Chan, MR, Thomas, CP, Torrealba, JR, et al. Recurrent atypical hemolytic uremic syndrome associated with factor I mutation in a living related renal transplant recipient. American Journal of Kidney Diseases. 2009;53(2):321.Google Scholar
Nadasdy, T. Thrombotic microangiopathy in renal allografts: the diagnostic challenge. Current Opinion in Organ Transplantation. 2014;19(3):283.Google Scholar
Loirat, C, Niaudet, P. The risk of recurrence of hemolytic uremic syndrome after renal transplantation in children. Pediatric Nephrology. 2003;18(11):1095.Google Scholar
Ferraris, JR, Ramirez, JA, Ruiz, S, et al. Shiga toxin-associated hemolytic uremic syndrome: absence of recurrence after renal transplantation. Pediatric Nephrology. 2002;17(10):809.Google Scholar
Spargo, B. The renal lesions in preeclampsia. In: Lindheimer, M, editor. Hypertension in Pregnancy. New York: Wiley Medical; 1976. p. 129.Google Scholar
Inward, CD, Howie, AJ, Fitzpatrick, MM, et al. Renal histopathology in fatal cases of diarrhoea-associated haemolytic uraemic syndrome. British Association for Paediatric Nephrology. 1997;11(5):556.Google Scholar
Abe, H, Tsuboi, N, Yukawa, S, et al. Thrombotic thrombocytopenic purpura complicating Sjogren’s syndrome with crescentic glomerulonephritis and membranous nephritis. Modern Rheumatology. 2004;14(2):174.Google Scholar
Chang, A, Kowalewska, J, Smith, KD, Nicosia, RF, Alpers, CE. A clinicopathologic study of thrombotic microangiopathy in the setting of IgA nephropathy. Clinical Nephrology. 2006;66(6):397.Google Scholar
Benz, K, Amann, K, Dittrich, K, Dotsch, J. Thrombotic microangiopathy as a complication in a patient with focal segmental glomerulosclerosis. Pediatric Nephrology. 2007;22(12):2125.Google Scholar
Chen, SF, Wang, H, Huang, YM, et al. Clinicopathologic characteristics and outcomes of renal thrombotic microangiopathy in anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis. Clinical Journal of the American Society of Nephrology. 2015;10(5):750.Google Scholar
Manenti, L, Gnappi, E, Vaglio, A, et al. Atypical haemolytic uraemic syndrome with underlying glomerulopathies. A case series and a review of the literature. Nephrology, Dialysis, Transplantation. 2013;28(9):2246.Google Scholar
El Karoui, K, Hill, GS, Karras, A, et al. A clinicopathologic study of thrombotic microangiopathy in IgA nephropathy. Journal of the American Society of Nephrology. 2012;23(1):137.Google Scholar
Schmitt, R, Krmar, RT, Kristoffersson, A, Soderberg, M, Karpman, D. IgA nephropathy associated with a novel N-terminal mutation in factor H. European Journal of Pediatrics. 2011;170(1):107.Google Scholar
Momose, A, Nakajima, T, Chiba, S, et al. A case of fibrillary glomerulonephritis associated with thrombotic microangiopathy and anti-glomerular basement membrane antibody. Nephron Extra. 2015;5(1):30.Google Scholar
Kanodia, KV, Vanikar, AV, Shah, PR, et al. C1q nephropathy with acute hemolytic uremic syndrome. Saudi Journal of Kidney Diseases and Transplantation. 2012;23(3):556.Google Scholar
Koster, FT, Boonpucknavig, V, Sujaho, S, Gilman, RH, Rahaman, MM. Renal histopathology in the hemolytic-uremic syndrome following shigellosis. Clinical Nephrology. 1984;21(2):126.Google Scholar
Thoenes, W, John, HD. Endotheliotropic (hemolytic) nephroangiopathy and its various manifestation forms (thrombotic microangiopathy, primary malignant nephrosclerosis, hemolytic-uremic syndrome). Klin Wochenschr. 1980;58(4):173.Google Scholar
Taylor, CM, Chua, C, Howie, AJ, Risdon, RA. Clinico-pathological findings in diarrhoea-negative haemolytic uraemic syndrome. Pediatric Nephrology. 2004;19(4):419.Google Scholar
Trostle, DC, Bedetti, CD, Steen, VD, et al. Renal vascular histology and morphometry in systemic sclerosis. A case-control autopsy study. Arthritis and Rheumatism. 1988;31(3):393.Google Scholar
Gonzalo, A, Mampaso, F, Gallego, N, et al. Hemolytic uremic syndrome with hypocomplementemia and deposits of IgM and C3 in the involved renal tissue. Clinical Nephrology. 1981;16(4):193.Google Scholar
Bohle, A, Grabensee, B, Fischer, R, Berg, E, Klust, H. On four cases of hemolytic-uremic syndrome without microangiopathy. Clinical Nephrology. 1985;24(2):88.Google Scholar
Tomita, M, Ochiai, M, Shu, S, et al. [A case of thrombotic microangiopathy with glomerular subendothelial IgA deposition due to bevacizumab]. Nihon Jinzo Gakkai shi. 2014;56(5):612.Google Scholar
Petrucco, OM, Thomson, NM, Lawrence, JR, Weldon, MW. Immunofluorescent studies in renal biopsies in pre-eclampsia. British Medical Journal. 1974;1(5906):473.Google Scholar
Shigematsu, H, Dikman, SH, Churg, J, Grishman, E, Duffy, JL. Mesangial involvement in hemolytic-uremic syndrome. A light and electron microscopic study. The American Journal of Pathology. 1976;85(2):349.Google Scholar
John, HD, Thoenes, W. The glomerular lesions in endotheliotropic hemolytic nephroangiopathy (hemolytic uremic syndrome, malignant nephrosclerosis, post partum renal insufficiency). Pathology, Research and Practice. 1982;173(3):236.Google Scholar
Taylor, FB Jr., Toh, CH, Hoots, WK, Wada, H, Levi, M. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thrombosis and Haemostasis. 2001;86(5):1327.Google Scholar
Moake, JL, Rudy, CK, Troll, JH, et al. Unusually large plasma factor VIII: vonWillebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. The New England Journal of Medicine. 1982;307(23):1432.Google Scholar
Furlan, M, Robles, R, Solenthaler, M, et al. Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. Blood. 1997;89(9):3097.Google Scholar
Levy, GG, Nichols, WC, Lian, EC, et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature. 2001;413(6855):488.Google Scholar
Moake, JL. Thrombotic microangiopathies. The New England Journal of Medicine. 2002;347(8):589.Google Scholar
Rieger, M, Mannucci, PM, Kremer Hovinga, JA, et al. ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases. Blood. 2005;106(4):1262.Google Scholar
Zheng, XL, Sadler, JE. Pathogenesis of thrombotic microangiopathies. Annual Review of Pathology. 2008;3:249.Google Scholar
Loirat, C, Veyradier, A, Girma, JP, Ribba, AS, Meyer, D. Thrombotic thrombocytopenic purpura associated with von Willebrand factor-cleaving protease (ADAMTS13) deficiency in children. Seminars in Thrombosis and Hemostasis. 2006;32(2):90.Google Scholar
Lammle, B, Kremer Hovinga, JA, George, JN. Acquired thrombotic thrombocytopenic purpura: ADAMTS13 activity, anti-ADAMTS13 autoantibodies and risk of recurrent disease. Haematologica. 2008;93(2):172.Google Scholar
Bianchi, V, Robles, R, Alberio, L, Furlan, M, Lammle, B. Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura. Blood. 2002;100(2):710.Google Scholar
George, JN, Terrell, DR, Vesely, SK, Kremer Hovinga, JA, Lammle, B. Thrombotic microangiopathic syndromes associated with drugs, HIV infection, hematopoietic stem cell transplantation and cancer. Presse Med. 2012;41(3 Pt 2):e177.Google Scholar
Peyvandi, F, Lavoretano, S, Palla, R, et al. ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission. Haematologica. 2008;93(2):232.Google Scholar
Remuzzi, G, Galbusera, M, Noris, M, et al. von Willebrand factor cleaving protease (ADAMTS13) is deficient in recurrent and familial thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Blood. 2002;100(3):778.Google Scholar
Lotta, LA, Wu, HM, Mackie, IJ, et al. Residual plasmatic activity of ADAMTS13 correlates with phenotype severity in congenital thrombotic thrombocytopenic purpura. Blood. 2012;120(2):440–8.Google Scholar
Ruiz-Torres, MP, Casiraghi, F, Galbusera, M, et al. Complement activation: the missing link between ADAMTS-13 deficiency and microvascular thrombosis of thrombotic microangiopathies. Thrombosis and Haemostasis. 2005;93(3):443.Google Scholar
Reti, M, Farkas, P, Csuka, D, et al. Complement activation in thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis. 2012;10(5):791.Google Scholar
Noris, M, Remuzzi, G. Atypical hemolytic-uremic syndrome. The New England Journal of Medicine. 2009;361(17):1676.Google Scholar
Hofer, J, Giner, T, Jozsi, M. Complement factor H-antibody-associated hemolytic uremic syndrome: pathogenesis, clinical presentation, and treatment. Seminars in Thrombosis and Hemostasis. 2014;40(4):431.Google Scholar
Jozsi, M, Licht, C, Strobel, S, et al. Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1/CFHR3 deficiency. Blood. 2008;111(3):1512.Google Scholar
Moore, I, Strain, L, Pappworth, I, et al. Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome. Blood. 2010;115(2):379.Google Scholar
Skerka, C, Jozsi, M, Zipfel, PF, Dragon-Durey, MA, Fremeaux-Bacchi, V. Autoantibodies in haemolytic uraemic syndrome (HUS). Thrombosis and Haemostasis. 2009;101(2):227.Google Scholar
Devaux, P, Christiansen, D, Fontaine, M, Gerlier, D. Control of C3b and C5b deposition by CD46 (membrane cofactor protein) after alternative but not classical complement activation. European Journal of Immunology. 1999;29(3):815.Google Scholar
Valoti, E, Alberti, M, Tortajada, A, et al. A novel atypical hemolytic uremic syndrome-associated hybrid CFHR1/CFH gene encoding a fusion protein that antagonizes factor H-dependent complement regulation. Journal of the American Society of Nephrology. 2015;26(1):209.Google Scholar
Schramm, EC, Roumenina, LT, Rybkine, T, et al. Mapping interactions between complement C3 and regulators using mutations in atypical hemolytic uremic syndrome. Blood. 2015;125(15):2359.Google Scholar
Funato, M, Uemura, O, Ushijima, K, et al. A complement factor B mutation in a large kindred with atypical hemolytic uremic syndrome. Journal of Clinical Immunology. 2014;34(6):691.Google Scholar
Sartz, L, Olin, AI, Kristoffersson, AC, et al. A novel C3 mutation causing increased formation of the C3 convertase in familial atypical hemolytic uremic syndrome. Journal of Immunology. 2012;188(4):2030.Google Scholar
Roumenina, LT, Frimat, M, Miller, EC, et al. A prevalent C3 mutation in aHUS patients causes a direct C3 convertase gain of function. Blood. 2012;119(18):4182.Google Scholar
Ermini, L, Goodship, TH, Strain, L, et al. Common genetic variants in complement genes other than CFH, CD46 and the CFHRs are not associated with aHUS. Molecular Immunology. 2012;49(4):640.Google Scholar
Kerr, H, Richards, A. Complement-mediated injury and protection of endothelium: lessons from atypical haemolytic uraemic syndrome. Immunobiology. 2012;217(2):195.Google Scholar
Caprioli, J, Noris, M, Brioschi, S, et al. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood. 2006;108(4):1267.Google Scholar
Fraser, ME, Fujinaga, M, Cherney, MM, et al. Structure of shiga toxin type 2 (Stx2) from Escherichia coli O157:H7. The Journal of Biological Chemistry. 2004;279(26):27511.Google Scholar
Lindberg, AA, Brown, JE, Stromberg, N, et al. Identification of the carbohydrate receptor for Shiga toxin produced by Shigella dysenteriae type 1. Journal of Biological Chemistry. 1987;262(4):1779.Google Scholar
Paton, JC, Paton, AW. Shiga toxin ‘goes retro’ in human primary kidney cells. Kidney International. 2006;70(12):2049.Google Scholar
Johannes, L, Romer, W. Shiga toxins – from cell biology to biomedical applications. Nature Reviews Microbiology. 2010;8(2):105.Google Scholar
Xicohtencatl-Cortes, J, Monteiro-Neto, V, Ledesma, MA, et al. Intestinal adherence associated with type IV pili of enterohemorrhagic Escherichia coli O157: H7. The Journal of Clinical Investigation. 2007;117(11):3519.Google Scholar
Hurley, BP, Thorpe, CM, Acheson, DW. Shiga toxin translocation across intestinal epithelial cells is enhanced by neutrophil transmigration. Infection and Immunity. 2001;69(10):6148.Google Scholar
te Loo, DM, Monnens, LA, van Der Velden, TJ, et al. Binding and transfer of verocytotoxin by polymorphonuclear leukocytes in hemolytic uremic syndrome. Blood. 2000;95(11):3396.Google Scholar
Petruzziello-Pellegrini, TN, Marsden, PA. Shiga toxin-associated hemolytic uremic syndrome: advances in pathogenesis and therapeutics. Current Opinion in Nephrology and Hypertension. 2012;21(4):433.Google Scholar
Matussek, A, Lauber, J, Bergau, A, et al. Molecular and functional analysis of Shiga toxin-induced response patterns in human vascular endothelial cells. Blood. 2003;102(4):1323.Google Scholar
Zanchi, C, Zoja, C, Morigi, M, et al. Fractalkine and CX3CR1 mediate leukocyte capture by endothelium in response to Shiga toxin. Journal of Immunology. 2008;181(2):1460.Google Scholar
Morigi, M, Galbusera, M, Binda, E, et al. Verotoxin-1-induced up-regulation of adhesive molecules renders microvascular endothelial cells thrombogenic at high shear stress. Blood. 2001;98(6):1828.Google Scholar
Nolasco, LH, Turner, NA, Bernardo, A, et al. Hemolytic uremic syndrome-associated Shiga toxins promote endothelial-cell secretion and impair ADAMTS13 cleavage of unusually large von Willebrand factor multimers. Blood. 2005;106(13):4199.Google Scholar
Liu, F, Huang, J, Sadler, JE. Shiga toxin (Stx)1B and Stx2B induce von Willebrand factor secretion from human umbilical vein endothelial cells through different signaling pathways. Blood. 2011;118(12):3392.Google Scholar
Huang, J, Haberichter, SL, Sadler, JE. The B subunits of Shiga-like toxins induce regulated VWF secretion in a phospholipase D1 dependent manner. Blood. 2012;120(5):1143–9.Google Scholar
Morigi, M, Galbusera, M, Gastoldi, S, et al. Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis. Journal of Immunology. 2011;187(1):172.Google Scholar
Koster, F, Levin, J, Walker, L, et al. Hemolytic-uremic syndrome after shigellosis. Relation to endotoxemia and circulating immune complexes. The New England Journal of Medicine. 1978;298(17):927.Google Scholar
Coratelli, P, Buongiorno, E, Passavanti, G. Endotoxemia in hemolytic uremic syndrome. Nephron. 1988;50(4):365.Google Scholar
Heyderman, RS, Fitzpatrick, MM, Barclay, GR. Haemolytic-uraemic syndrome. Lancet. 1994;343(8904):1042.Google Scholar
Louise, CB, Obrig, TG. Shiga toxin-associated hemolytic-uremic syndrome: combined cytotoxic effects of Shiga toxin, interleukin-1 beta, and tumor necrosis factor alpha on human vascular endothelial cells in vitro. Infection and Immunity. 1991;59(11):4173.Google Scholar
Louise, CB, Obrig, TG. Shiga toxin-associated hemolytic uremic syndrome: combined cytotoxic effects of shiga toxin and lipopolysaccharide (endotoxin) on human vascular endothelial cells in vitro. Infection and Immunity. 1992;60(4):1536.Google Scholar
Edwards, IR, Aronson, JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000;356(9237):1255.Google Scholar
Gottschall, JL, Neahring, B, McFarland, JG, et al. Quinine-induced immune thrombocytopenia with hemolytic uremic syndrome: clinical and serological findings in nine patients and review of literature. American Journal of Hematology. 1994;47(4):283.Google Scholar
Kojouri, K, Vesely, SK, George, JN. Quinine-associated thrombotic thrombocytopenic purpura–hemolytic uremic syndrome: frequency, clinical features, and long-term outcomes. Annals of Internal Medicine. 2001;135(12):1047.Google Scholar
Huynh, M, Chee, K, Lau, DH. Thrombotic thrombocytopenic purpura associated with quetiapine. The Annals of Pharmacotherapy. 2005;39(7–8):1346.Google Scholar
Saif, MW, Xyla, V, Makrilia, N, Bliziotis, I, Syrigos, K. Thrombotic microangiopathy associated with gemcitabine: rare but real. Expert Opinion on Drug Safety. 2009;8(3):257.Google Scholar
Sartelet, H, Toupance, O, Lorenzato, M, et al. Sirolimus-induced thrombotic microangiopathy is associated with decreased expression of vascular endothelial growth factor in kidneys. American Journal of Transplantation. 2005;5(10):2441.Google Scholar
Eremina, V, Quaggin, SE. Biology of anti-angiogenic therapy-induced thrombotic microangiopathy. Seminars in Nephrology. 2010;30(6):582.Google Scholar
Sanchez Chinchilla, D, Pinto, S, Hoppe, B, et al. Complement mutations in diacylglycerol kinase-epsilon-associated atypical hemolytic uremic syndrome. Clinical Journal of the American Society of Nephrology. 2014;9(9):1611.Google Scholar
Alpers, CE. Light at the end of the TUNEL: HIV-associated thrombotic microangiopathy. Kidney International. 2003;63(1):385.Google Scholar
Gilardin, L, Malak, S, Schoindre, Y, et al. [Human immunodeficiency virus-associated thrombotic microangiopathies]. La Revue de Medecine Interne. 2012;33(5):259.Google Scholar
Coats, MT, Murphy, T, Paton, JC, Gray, B, Briles, DE. Exposure of Thomsen–Friedenreich antigen in Streptococcus pneumoniae infection is dependent on pneumococcal neuraminidase A. Microbial Pathogenesis. 2011;50(6):343.Google Scholar
Copelovitch, L, Kaplan, BS. Streptococcus pneumoniae-associated hemolytic uremic syndrome. Pediatric Nephrology. 2008;23(11):1951.Google Scholar
Klein, PJ, Bulla, M, Newman, RA, et al. Thomsen–Friedenreich antigen in haemolytic-uraemic syndrome. Lancet. 1977;2(8046):1024.Google Scholar
Copelovitch, L, Kaplan, BS. Streptococcus pneumoniae-associated hemolytic uremic syndrome. Pediatr Nephrol. 2008;23(11):1951–6.Google Scholar
Venkatesha, S, Toporsian, M, Lam, C, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nature Medicine. 2006;12(6):642.Google Scholar
Levine, RJ, Maynard, SE, Qian, C, et al. Circulating angiogenic factors and the risk of preeclampsia. New England Journal of Med. 2004;350(7):672.Google Scholar
Garovic, VD, Wagner, SJ, Petrovic, LM, et al. Glomerular expression of nephrin and synaptopodin, but not podocin, is decreased in kidney sections from women with preeclampsia. Nephrology Dialysis and Transplantation. 2007;22(4):1136.Google Scholar
Roncone, D, Satoskar, A, Nadasdy, T, Monk, JP, Rovin, BH. Proteinuria in a patient receiving anti-VEGF therapy for metastatic renal cell carcinoma. Nature Clinical Practice Nephrology. 2007;3(5):287.Google Scholar
Jiang, H, An, X, Li, Y, et al. Clinical features and prognostic factors of thrombotic thrombocytopenic purpura associated with systemic lupus erythematosus: a literature review of 105 cases from 1999 to 2011. Clinical Rheumatology. 2014;33(3):419.Google Scholar
Changcharoen, B, Bolger, DT Jr. Thrombotic thrombocytopenic purpura as an initial presentation of systemic lupus erythematosus with acquired ADAMTS 13 antibody. BMJ Case Reports. 2015 Feb 20; 2015. pii: bcr 2014208477. doi:10.1136/bcr-2014-208477.Google Scholar
Tomov, S, Lazarchick, J, Self, SE, Bruner, ET, Budisavljevic, MN. Kidney-limited thrombotic microangiopathy in patients with SLE treated with romiplostim. Lupus. 2013;22(5):504.Google Scholar
Lee, S, Sharma, K. The pathogenesis of fibrosis and renal disease in scleroderma: recent insights from glomerulosclerosis. Current Rheumatology Reports. 2004;6(2):141.Google Scholar
Pierangeli, SS, Chen, PP, Raschi, E, et al. Antiphospholipid antibodies and the antiphospholipid syndrome: pathogenic mechanisms. Seminars in Thrombosis and Hemostasis. 2008;34(3):236.Google Scholar
Yang, CD, Hwang, KK, Yan, W, et al. Identification of anti-plasmin antibodies in the antiphospholipid syndrome that inhibit degradation of fibrin. Journal of Immunology. 2004;172(9):5765.Google Scholar
Montiel-Manzano, G, Romay-Penabad, Z, Papalardo de Martinez, E, et al. In vivo effects of an inhibitor of nuclear factor-kappa B on thrombogenic properties of antiphospholipid antibodies. Annals of the New York Academy of Sciences. 2007;1108:540.Google Scholar
Nojima, J, Suehisa, E, Kuratsune, H, et al. Platelet activation induced by combined effects of anticardiolipin and lupus anticoagulant IgG antibodies in patients with systemic lupus erythematosus – possible association with thrombotic and thrombocytopenic complications. Thrombosis and Haemostasis. 1999;81(3):436.Google Scholar
Vega-Ostertag, M, Casper, K, Swerlick, R, et al. Involvement of p38 MAPK in the up-regulation of tissue factor on endothelial cells by antiphospholipid antibodies. Arthritis and Rheumatism. 2005;52(5):1545.Google Scholar
Pierangeli, SS, Girardi, G, Vega-Ostertag, M, et al. Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia. Arthritis and Rheumatism. 2005;52(7):2120.Google Scholar
de Groot, PG, Derksen, RH. Pathophysiology of the antiphospholipid syndrome. Journal of Thrombosis and Haemostasis. 2005;3(8):1854.Google Scholar
Antignac, C, Gubler, MC, Leverger, G, Broyer, M, Habib, R. Delayed renal failure with extensive mesangiolysis following bone marrow transplantation. Kidney International. 1989;35(6):1336.Google Scholar
Jodele, S, Laskin, BL, Dandoy, CE, et al. A new paradigm: diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury. Blood Reviews. 2015;29(3):191.Google Scholar
Garcia-Martin, P, Alarcon-Payer, C, Lopez-Fernandez, E, et al. Transplantation-Associated thrombotic microangiopathy in patients treated with sirolimus and cyclosporine as salvage therapy for graft-versus-host disease. The Annals of Pharmacotherapy. 2015;49(9):986–94.Google Scholar
Laskin, BL, Goebel, J, Davies, SM, et al. Early clinical indicators of transplant-associated thrombotic microangiopathy in pediatric neuroblastoma patients undergoing auto-SCT. Bone Marrow Transplantation. 2011;46(5):682.Google Scholar
Robson, M, Cote, I, Abbs, I, Koffman, G, Goldsmith, D. Thrombotic micro-angiopathy with sirolimus-based immunosuppression: potentiation of calcineurin-inhibitor-induced endothelial damage? American Journal of Transplantation. 2003;3(3):324.Google Scholar
Saikali, JA, Truong, LD, Suki, WN. Sirolimus may promote thrombotic microangiopathy. American Journal of Transplantation. 2003;3(2):229.CrossRefGoogle ScholarPubMed
Verbiest, A, Pirenne, J, Dierickx, D. De novo thrombotic microangiopathy after non-renal solid organ transplantation. Blood Reviews. 2014;28(6):269.Google Scholar
Waiser, J, Budde, K, Rudolph, B, Ortner, MA, Neumayer, HH. De novo hemolytic uremic syndrome postrenal transplant after cytomegalovirus infection. American Journal of Kidney Diseases. 1999;34(3):556.Google Scholar
Murer, L, Zacchello, G, Bianchi, D, et al. Thrombotic microangiopathy associated with parvovirus B 19 infection after renal transplantation. Journal of the American Society of Nephrology. 2000;11(6):1132.Google Scholar
Petrogiannis-Haliotis, T, Sakoulas, G, Kirby, J, et al. BK-related polyomavirus vasculopathy in a renal-transplant recipient. New England Journal of Medicine. 2001;345(17):1250.Google Scholar
Gohh, RY, Williams, ME, Crosson, AW, Federman, M, Zambetti, FX. Late renal allograft failure secondary to thrombotic microangiopathy associated with disseminated malignancy. American Journal of Nephrology. 1997;17(2):176.Google Scholar
Pelle, G, Xu, Y, Khoury, N, Mougenot, B, Rondeau, E. Thrombotic microangiopathy in marginal kidneys after sirolimus use. American Journal of Kidney Diseases. 2005;46(6):1124.Google Scholar
Evens, AM, Kwaan, HC, Kaufman, DB, Bennett, CL. TTP/HUS occurring in a simultaneous pancreas/kidney transplant recipient after clopidogrel treatment: evidence of a nonimmunological etiology. Transplantation. 2002;74(6):885.Google Scholar
Jumani, A, Hala, K, Tahir, S, et al. Causes of acute thrombotic microangiopathy in patients receiving kidney transplantation. Experimental and Clinical Transplantation. 2004;2(2):268.Google Scholar
Baid, S, Pascual, M, Williams, WW Jr., et al. Renal thrombotic microangiopathy associated with anticardiolipin antibodies in hepatitis C-positive renal allograft recipients. Journal of the American Society of Nephrology. 1999;10(1):146.Google Scholar
Sreedharanunni, S, Joshi, K, Duggal, R, et al. An analysis of transplant glomerulopathy and thrombotic microangiopathy in kidney transplant biopsies. Transplant International. 2014;27(8):784.Google Scholar
George, JN. Congenital thrombotic thrombocytopenic purpura: lessons for recognition and management of rare syndromes. Pediatric Blood & Cancer. 2008;50(5):947.Google Scholar
Fitzpatrick, MM, Walters, MD, Trompeter, RS, Dillon, MJ, Barratt, TM. Atypical (non-diarrhea-associated) hemolytic-uremic syndrome in childhood. The Journal of Pediatrics. 1993;122(4):532.Google Scholar
Loirat, C, Fakhouri, F, Ariceta, G, et al. An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol. 2016;31(1):15–39.Google Scholar
Remuzzi, G, Ruggenenti, P. The hemolytic uremic syndrome. Kidney International. 1995;48(1):2.Google Scholar
Garg, AX, Suri, RS, Barrowman, N, et al. Long-term renal prognosis of diarrhea-associated hemolytic uremic syndrome: a systematic review, meta-analysis, and meta-regression. Journal of the American Medical Association. 2003;290(10):1360.Google Scholar
Nathoo, KJ, Porteous, JE, Siziya, S, Wellington, M, Mason, E. Predictors of mortality in children hospitalized with dysentery in Harare, Zimbabwe. Central African Journal of Medicine. 1998;44(11):272.Google Scholar
Houdouin, V, Doit, C, Mariani, P, et al. A pediatric cluster of Shigella dysenteriae serotype 1 diarrhea with hemolytic uremic syndrome in 2 families from France. Clinical Infectious Diseases. 2004;38(9):e96.Google Scholar
Bennish, ML, Khan, WA, Begum, M, et al. Low risk of hemolytic uremic syndrome after early effective antimicrobial therapy for Shigella dysenteriae type 1 infection in Bangladesh. Clinical Infectious Diseases. 2006;42(3):356.Google Scholar